Westfield Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Westfield Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,153,163	Closed	-$37M	–	301
2016 Q4	$37M	Buy	1,153,163 +22,735	+2%	+$970K	0.32%	107
2016 Q3	$56.5M	Sell	1,130,428 -22,948	-2%	-$953K	0.46%	78
2016 Q2	$48.9M	Buy	1,153,376 +120,432	+12%	+$6.56M	0.4%	87
2016 Q1	$68M	Buy	1,032,944 +110,730	+12%	+$5.78M	0.52%	64
2015 Q4	$57.3M	Buy	922,214 +94,595	+11%	+$6.66M	0.39%	88
2015 Q3	$55.4M	Buy	827,619 +207,159	+33%	+$16.9M	0.39%	88
2015 Q2	$60.4M	Buy	620,460 +251,418	+68%	+$23.9M	0.37%	95
2015 Q1	$34.5M	Buy	+369,042	New	+$31.4M	0.2%	144
2013 Q4	–	Sell	-179,194	Closed	-$5.34M	–	368
2013 Q3	$5.34M	Sell	179,194 -10,420	-5%	-$365K	0.03%	248
2013 Q2	$10.1M	Buy	+189,614	New	+$8.31M	0.07%	240

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management's MACK Position: Q1 2017 in Review

Westfield Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2017, closing a stake of 1,153,163 shares — an estimated $37M sold.

Westfield Capital Management first reported a position in MACK in Q2 2013 and held it in 10 quarters. The position peaked at $68M in Q1 2016. 116 funds tracked by Wall St. Rank hold MACK as of Q1 2017.

Westfield Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Westfield Capital Management sold 1,153,163 Merrimack Pharmaceuticals, Inc. shares in Q1 2017, an estimated $37M.
Westfield Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 10 quarters.
Westfield Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $68M in Q1 2016.
116 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2017.

Based on Westfield Capital Management's 13F filing for Q1 2017, filed 12 May 2017.